BV also directly targeted CD30<sup>+</sup> tumor-infiltrating regulatory T cells (TI-Tregs), and activated anti-tumor immunity mediated by dendritic cells and CD8<sup>+</sup> T cells. This evidence concerns the gene TNFRSF8 and neoplasm.